TRAVERE THERAPEUTICS, INC. Proceeds from Notes Payable
TRAVERE THERAPEUTICS, INC. (TVTX) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2017-03-01
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2015-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2014-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2014-09-30 was $1.00M.
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2013-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for fiscal 2016 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for fiscal 2014 was $42.92M.
- TRAVERE THERAPEUTICS, INC. proceeds from notes payable for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 22 month | Proceeds from Notes Payable 25 month | Proceeds from Notes Payable 28 month | Proceeds from Notes Payable 31 month | Proceeds from Notes Payable 34 month |
|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | ||||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 | |||||||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-06 | ||||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $1.00M derived: sum of 2 quarters · filed 2017-03-01 | $42.92M 10-K · filed 2017-03-01 | ||||||
| 2014-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $42.92M 10-Q · filed 2015-11-06 | |||||||
| 2014-06-30 | $41.92M 10-Q · filed 2015-08-10 | ||||||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $0.00 10-K · filed 2016-02-26 | $930.00K 10-K/A · filed 2015-07-09 | ||||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-13 | $930.00K 10-Q/A · filed 2015-07-09 | |||||||
| 2013-06-30 | $930.00K 10-Q · filed 2013-09-16 | ||||||||
| 2013-03-31 | $0.00 10-Q/A · filed 2013-09-16 | $0.00 derived: sum of 2 quarters · filed 2015-07-09 | $91.24K derived: sum of 3 quarters · filed 2015-07-09 | $91.24K derived: sum of 4 quarters · filed 2015-07-09 | $930.00K 10-Q/A · filed 2013-09-16 | ||||
| 2012-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | $91.24K derived: sum of 2 quarters · filed 2015-07-09 | $91.24K derived: sum of 3 quarters · filed 2015-07-09 | $930.00K 10-K/A · filed 2015-07-09 | $930.00K 10-K/A · filed 2013-09-16 | ||||
| 2012-09-30 | $91.24K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2015-07-09 | $91.24K derived: sum of 2 quarters · filed 2015-07-09 | $930.00K 10-Q/A · filed 2015-07-09 | ||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2013-09-16 | $838.76K 10-Q · filed 2013-09-16 | |||||||
| 2012-03-31 | $838.76K 10-Q/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |